Therapeutic equivalence: Fallacies and falsification

Statistics in Medicine

Volumn 22, Issue 5, 2003, Pages 741-762

  Garrett, Andrew D ^a  

^a IQVIA   (United States)

Author keywords

Analysis populations; Covariate adjustment; Drug regulation; Equivalence margins; Logistic regression; Non inferiority

Indexed keywords

ANTIASTHMATIC AGENT; ANTIINFECTIVE AGENT; CHLOROFLUOROCARBON; PLACEBO;

ASTHMA; BIOEQUIVALENCE; CLINICAL STUDY; COVARIANCE; DRUG CONTROL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RESEARCH; HUMAN; METHODOLOGY; PATIENT SELECTION; PRACTICE GUIDELINE; REVIEW; SAMPLE SIZE; STATISTICAL ANALYSIS;

DRUG EVALUATION; HUMANS; MODELS, STATISTICAL; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SAMPLE SIZE; THERAPEUTIC EQUIVALENCY;

EID: 0037445366     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.1360     Document Type: Review

References (41)

1. Dunnett CW, Gent M. Significance testing to establish equivalence between treatments, with special reference to data in the form of 2 × 2 tables. Biometrics 1977; 33:593-602.
2. CPMP. Note for guidance on the investigation of bioavailability and bioequivalence. (CPMP/EWP/QWP/1401/98) 26 July 2001. http://www.emea.eu.int/pdfs/human/ewp/140198en.pdf [last accessed 28/08/01].
3. FDA. Guidance for industry. Bioavailability and bioequivalence studies for orally administered drug products-general considerations. October 2000. http://www.fda.gov/cder/guidance/3615fnl.htm [last accessed 15/05/02].
4. FDA. Guidance for industry. Statistical approaches to establishing bioequivalence. January 2001. http://www. fda.gov/cder/guidance/3616fnl.htm [last accessed 15/05/02].
5. ICH topic E9. Statistical principles for clinical trials. (CPMP/ICH/363/96) 5 February 1998. http://www.emea. eu.int/pdfs/human/ich/036396en.pdf [last accessed 28/08/01].
6. CPMP. Points to consider on switching between superiority and non-inferiority. (CPMP/EWP/482/99) 27 July 2000. http://www.emea.eu.int/pdfs/human/ewp/048299en.pdf [last accessed 28/08/01].
7. ICH topic E10. Choice of control group in clinical trials. (CPMP/ICH/364/96) 27 July 2000. http://www. emea.eu.int/pdfs/human/ich/036496en.pdf [last accessed 28/08/01].
8. Bristol DR. Clinical equivalence. Journal of Biopharmaceutical Statistics 1999; 9:549-561.
9. Senn S. Falsificationism and clinical trials. Statistics in Medicine 1991; 10:1679-1692.
10. Senn S. Statistical issues in bioequivalence. Statistics in Medicine 2001; 20:2785-2799.
11. Röhmel J. Statistical considerations of FDA and CPMP rules for the investigation of new anti-bacterial products. Statistics in Medicine 2001; 20:2561-2571.
12. Morikawa T, Yoshida M. A useful testing strategy in phase III trials: combined test of superiority and test of equivalence. Journal of Biopharmaceutical Statistics 1995; 5:297-306.
13. Röhmel J. Therapeutic equivalence investigations: statistical considerations. Statistics in Medicine 1998; 17: 1703-1714.
14. FDA. Guidance for industry. Evaluating clinical studies of antimicrobials in the division of anti-infective drug products. Page 87, 17 February 1997. http://www.fda.gov/cder/guidance/draft9al.pdf [last accessed 24/08/01].
15. CPMP. Note for guidance on evaluation of new anti-bacterial medicinal products. (CPMP/EWP/558/95) April 1997. http://www.emea.eu.int/pdfs/human/ewp/055895en.pdf [last accessed 28/08/01].
16. Cox D. Analysis of Binary Data. Chapman and Hall: London, 1970; 20-21.
17. Tu D. On the use of the ratio or the odds ratio of cure rates in therapeutic equivalence clinical trials with binary endpoints. Journal of Biopharmaceutical Statistics 1998; 8:263-282.
18. Senn S. Consensus and controversy in pharmaceutical statistics (with discussion). Journal of the Royal Statistical Society, Series D, 2000; 49:135-176.
19. CPMP. Concept paper on the development of a committee for proprietary medicinal products (CPMP) points to consider on biostatistical/methodological issues arising from recent CPMP discussions on licensing applications: choice of delta. (CPMP/EWP/2158/99) 23 September 1999. http://www.emea.eu.int/pdfs/human/ewp/215899en.pdf [last accessed 28/08/01].
20. Phillips A, Ebbutt A, France L, Morgan D. The international conference on harmonization guideline 'statistical principles for clinical trials': issues in applying the guideline in practice. Drug Information Journal 2000; 34:337-348.
21. Nelder JA, Wedderburn RWM. Generalised linear models. Journal of the Royal Statistical Society, Series A 1972; 135:370-384.
22. Hutton JL. Number needed to treat: properties and problems (with comments). Journal of the Royal Statistical Society, Series A, 2000; 163:403-419.
23. Lewis JA, Machin D. Intention to treat-who should use ITT? British Journal of Cancer 1993; 68:647-650.
24. CPMP note for guidance (III/3630/92-EN). Biostatistical methodology in clinical trials in applications for marketing authorizations for medicinal products. Statistics in Medicine 1995; 14:1659-1682.
25. Goldberg J. The effects of misclassification on the bias in the difference between two proportions and the relative odds in the fourfold table. Journal of the American Statistical Association 1975; 70:561-567.
26. Choi SC, Lu IL. Effect of non-random missing data mechanisms in clinical trials. Statistics in Medicine 1995; 14:2675-2684.
27. Little RJA, Rubin DB. Statistical Analysis with Missing Data. Wiley: New York, 1987.
28. Makuch RW, Simon R. Sample size requirements for evaluating a conservative therapy. Cancer Treat Reports 1978; 62:1037-1040.
29. SAS Institute Inc., SAS/STAT® User's Guide, Version 6, fourth, Volume 2. SAS Institute Inc.: Cary, NC, 1989.
30. Ebbutt AF, Frith L. Practical issues in equivalence trials. Statistics in Medicine 1998; 17:1691-1701.
31. CPMP. Points to consider on multiplicity issues in clinical trials. (CPMP/EWP/908/99) 26 July 2001. http://www.emea.eu.int/pdfs/human/ewp/090899en.pdf [last accessed 16/10/01].
32. Smith C, Burley C, Ireson M. Clinical trials of antibacterial agents: a practical guide to design and analysis. Journal of Antimicrobial Chemotherapy 1998; 41:467-480.
33. Gail MH. Adjusting for covariates that have the same distribution in exposed and unexposed cohorts. In Modern Statistical Methods in Chronic Disease Epidemiology, Moolgavkar SH, Prentice RL (eds). Wiley: New York, 1986; 3-18.
34. Robinson LD, Jewell NP. Some surprising results about covariate adjustment in logistic regression models. International Statistical Review 1991; 58(2):227-240.
35. Robinson LD, Dorroh JR, Lein D, Tiku ML. The effects of covariate adjustment in generalized linear models. Communications in Statistics-Theory and Methods 1998; 27:1653-1675.
36. Lee PN. Simple methods for checking for possible errors in reported odds ratios, relative risks and confidence intervals. Statistics in Medicine 1999; 18:1973-1981.
37. SAS Institute Inc. SAS/STAT® Software: Changes and enhancements through release 6.11. SAS Institute Inc.: NC, 1996.
38. CPMP. Points to consider on biostatistical/methodological issues arising from recent CPMP discussions on licensing applications: superiority, non-inferiority and equivalence. (CPMP/EWP/482/99 draft) 23 September 1999.
39. Hsieh FY, Bloch DA, Larsen MD. A simple method of sample size calculation for linear and logistic regression. Statistics in Medicine 1998; 17:1623-1634.
40. Whitehead J. Sample size calculations for ordered categorical data. Statistics in Medicine 1993; 12:2257-2271.
41. Ford I, Norrie J, Atimadis S. Model inconsistency, illustrated by the Cox proportional hazards model. Statistics in Medicine 1995; 14:735-746.